Abstract:Background: Depression is a common complication of cardiovascular disease, which deteriorates cardiac function. Shuangxinfang (psycho-cardiology formula, PCF) was reported to alleviate myocardial ischemia injury and improve depression-like behavior. Interestingly, our previous proteomics study predicted that the protein S100A9 appeared as an important target, and macrophage/microglial inflammation might be involved in the process of PCF improving depression induced by acute myocardial infarction (AMI). This study aims to validate the proteomics results. Methods: AMI rat models were established in vivo, followed by the administration of PCF or ABR-215757 (also named paquinimod, inhibiting S100A9 binding to TLR4) for 5 days. Forced swimming test (FST) and open field test (OFT) were applied to record depression-like behavior, and echocardiography was employed to evaluate cardiac function. Morphological changes of cardiomyocytes were assessed by HE staining and TUNEL staining on day 7 after cardiac surgery, as well as Masson trichrome staining on day 21. Hippocampal neurogenesis was determined by Nissl staining, while 5-hydroxytryptamine (5-HT), tryptophan/kynurenine ratio, and brain-derived neurotrophic factor (BDNF) in the hippocampus were analyzed as biochemical indicators of depression. We employed RT-qPCR, western blotting, and immunofluorescence to detect the expression of pathway-related genes and proteins. Myocardial and hippocampal expression of inflammatory factors were performed by ELISA. The activation of macrophage and microglia was assessed via immunoreaction using CD68 and Iba1, respectively. For in vitro confirmation, BV2 cells were primed with recombinant protein S100A9 and then treated with PCF serum or ferulic acid to determine alterations in microglial inflammation. Results: Rats in the AMI group showed heart function deterioration and depression-like behavior. Coronary ligation not only brought about myocardial inflammation, cell apoptosis, and fibrosis but also reduced the neurogenesis, elevated the tryptophan/kynurenine ratio, and decreased the content of 5-HT. PCF could ameliorate the pathological and phenotypic changes in the heart and brain and inhibit the expression of the S100A9 protein, the activation of the microglial cell, and the secretion of IL-1β and TNF-α raised by AMI. ABR-215757 showed therapeutic effect and molecular biological mechanisms similar to PCF. Treatment with PCF serum or ferulic acid in vitro was proved to efficiently block the hyperactivation of BV2 cells and increment of cytokine contents induced by recombinant protein S100A9. Conclusion: We identify S100A9 as a novel and potent regulator of inflammation in both the heart and brain. Macrophage/microglia inflammation mediated by S100A9 is considered a pivotal pathogenic in depression after AMI and a major pathway for the treatment of PCF, suggesting that PCF is a promising therapeutic candidate for psycho-cardiology disease.

Photoresponsive Vaccine‐Like CAR‐M System with High‐Efficiency Central Immune Regulation for Inflammation‐Related Depression

Engineered Nanoerythrocyte Alleviate Central Nervous System Inflammation by Regulating the Polarization of Inflammatory Microglia

Facile engineered macrophages-derived exosomes-functionalized PLGA nanocarrier for targeted delivery of dual drug formulation against neuroinflammation by modulation of microglial polarization in a post-stroke depression rat model

Tert-Butylhydroquinone Prevents Neuroinflammation and Relieves Depression Via Regulation of NLRP3 Signaling in Mice

Photothermal Modulation of Depression‐Related Ion Channel Function through Conjugated Polymer Nanoparticles

Hypochlorous Acid-Activated Multifunctional Fluorescence Platform for Depression Therapy and Antidepressant Efficacy Evaluation

Transferrin-modified Carboxymethyl Chitosan-Chitosan Nanoparticles As an Efficient Delivery Carrier for Targeted Therapy of Depression

Cell-liposome Delivery System Based on Neuroinflammation to Target the Amygdala for Ameliorating Depressive-Like Behaviors

Shuangxinfang Prevents S100A9-Induced Macrophage/Microglial Inflammation to Improve Cardiac Function and Depression-Like Behavior in Rats After Acute Myocardial Infarction

Brain‐Targeted Black Phosphorus‐Based Nanotherapeutic Platform for Enhanced Hypericin Delivery in Depression

Monocyte mediated brain targeting delivery of macromolecular drug for the therapy of depression

Microglial NLRP3 inflammasome-mediated neuroinflammation and therapeutic strategies in depression

Advanced Therapies for Traumatic Central Nervous System Injury: Delivery Strategy Reinforced Efficient Microglial Manipulation

Chemical dampening of Ly6C(hi) monocytes in the periphery produces anti-depressant effects in mice

Anti-Neuroinflammatory Effects of a Macrocyclic Peptide-Peptoid Hybrid in Lipopolysaccharide-Stimulated BV2 Microglial Cells

Cynaroside improved depressive-like behavior in CUMS mice by suppressing microglial inflammation and ferroptosis

Microglia Sing the Prelude of Neuroinflammation-Associated Depression

Near-infrared Light-Controlled Regulation of Intracellular Calcium to Modulate Macrophage Polarization

Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression

Mechanistic insights into the anti-depressant effect of emodin: an integrated systems pharmacology study and experimental validation

NMC-4 Ameliorates Depression-Like Behavior and Neuroinflammation Caused by Chronic Unpredictable Mild Stress